Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
Immix Biopharma priced a $150 million underwritten offering of 16.8 million shares at $8.94 per share. The company intends to use the net proceeds to fund the development of its lead CAR-T candidate NXC-201, working capital, and general corporate purposes. Management stated that the proceeds, combined with existing cash, will fund operations into mid-2028.
Key figures
- Deal Value Usd
- 150000000
- Offering Price
- 8.94
- Shares Offered
- 16778524
- Cash runway extension
- mid-2028
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.